D. Barnes

发表

R. Camplejohn, D. Barnes, 1996, Journal of Mammary Gland Biology and Neoplasia.

The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target.

D. Lane, D. Barnes, S. Picksley, 1996, Acta oncologica.

A possible screening test for inherited p53-related defects based on the apoptotic response of peripheral blood lymphocytes to DNA damage.

R. Camplejohn, D. Barnes, P. Perry, 1995, British Journal of Cancer.

Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family

J. Varley, R. Camplejohn, D. Barnes, 1997, Oncogene.

Characterization of p53 oligomerization domain mutations isolated from Li–Fraumeni and Li–Fraumeni like family members

R. Camplejohn, T. Hupp, D. Barnes, 1998, Oncogene.

Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli.

J. Bartek, D. Lane, B. Vojtesek, 1992, Journal of cell science.

Cyclin D1 in Breast Cancer

D. Barnes, C. Gillett, 2004, Breast Cancer Research and Treatment.

Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors.

C. Mathew, L. Bobrow, D. Barnes, 1996, Cancer letters.

Multiple tissue core arrays in histopathology research: a validation study

D. Barnes, C. Gillett, R. Springall, 2000, The Journal of pathology.

Epstein-Barr virus in epithelial cell tumors: a breast cancer study.

B E Griffin, D M Barnes, I. Fentiman, 1995, Cancer research.

Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer.

A. Hanby, D. Sheer, D. Barnes, 1999, Cancer research.

Quality assurance of predictive markers in breast cancer.

D. Barnes, A. Rhodes, 2004, Methods in molecular medicine.

Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays.

L. Bobrow, D. Barnes, B. Jasani, 2001, American journal of clinical pathology.

Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening

D. Barnes, B. Jasani, K. Miller, 2000, Journal of clinical pathology.

Molecular pathology of Breast Cancer: Prognostic and predictive markers in this century and the next

D. Barnes, 1999, Breast cancer.

Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance.

L. Beex, D. Barnes, R. Millis, 1998, European journal of cancer.

c‐erbB‐2 amplification in mammary carcinoma

D. Barnes, 1993, Journal of cellular biochemistry. Supplement.

Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients.

D. Barnes, R. Rubens, P. Smith, 1996, British Journal of Cancer.

The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre.

C. E. Gillett, M. A. Richards, W. Gregory, 1995, British Journal of Cancer.

Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue.

A. Harris, C. Wolf, D. Barnes, 1990, Carcinogenesis.

Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours.

J. Bartek, J. Lukas, J. Bártková, 1993, European journal of cancer.

A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells.

D. Barnes, L. Erickson, K. Micetich, 1985, Cancer research.

Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer

R. Eeles, A. Ardern-Jones, S. Edwards, 1998, International journal of cancer.

Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer.

N. Lemoine, D. Barnes, N. Lemoine, 1990, Oncogene.

Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique.

D. Lane, B. Vojtesek, D. Barnes, 1993, British Journal of Cancer.

p53 immunoreactivity in human malignant melanoma and dysplastic naevi

D. Barnes, J. McGregor, E. Dublin, 1993, The British journal of dermatology.

The Science of Laboratory Diagnosis.

D. Barnes, 2000 .

Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival.

P. Hasleton, D. Barnes, N. Thatcher, 1989, British Journal of Cancer.

Expression of epidermal growth factor receptor (EGF-R) in human lung tumours.

P. Hasleton, D. Barnes, W. Gullick, 1986, British Journal of Cancer.

Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinomain situ

D. Barnes, J. Meyer, W. Gullick, 1991, Breast Cancer Research and Treatment.

Immunohistochemical detection of parathyroid hormone related protein in the primary tumours of hypercalcaemic breast cancer patients

D. Barnes, R. Rubens, R. Coleman, 1995 .

Progesterone receptor measurement by isoelectric focusing: a potential microassay.

D. Barnes, R. Harland, E. Hayward, 1983, Clinica chimica acta; international journal of clinical chemistry.

Extended role for needle biopsy in the management of carcinoma of the breast

A. Howell, D. Barnes, L. Turnbull, 1989, The British journal of surgery.

Apoptosis, ageing and cancer susceptibility

R. Eeles, A. Ardern-Jones, D. Easton, 2003, British Journal of Cancer.

TGF alpha and TGF beta expression in mammary carcinoma

D. Barnes, E. Dublin, D. Levison, 1993, The Journal of pathology.

Combined effects of streptozotocin and mitozolomide against four human cell lines of the Mer+ phenotype.

D. Barnes, N. Gibson, L. Erickson, 1986, Cancer research.

Amplification and Over-Expression of the MDM2 Gene in Human Soft Tissue Tumours

C. Cooper, B. Gusterson, C. Fisher, 1997, Sarcoma.

Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells.

R. Fisher, D. Barnes, B. Futscher, 1989, Cancer communications.

Variation of receptor status in cancer of the breast.

A. Howell, D. Barnes, G. Ribeiro, 1983, British Journal of Cancer.

Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384

G. Marek, D. Barnes, L. Ereshefsky, 2013, Translational Psychiatry.

Identification of missense and truncating mutations in the BRCA1 gene in sporadic and familial breast and ovarian cancer

C. Mathew, D. Barnes, S. Hodgson, 1998, Genes, chromosomes & cancer.

Steroid Receptors in Human Meningioma

H. Whitwell, D. Barnes, K. S. Paul, 1984, Clinical neuropharmacology.

1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking.

R. Fisher, K. Albain, D. Barnes, 1989, Cancer research.

Effect of tamoxifen upon cell DNA analysis by flow cytometry in primary carcinoma of the breast.

A. Howell, D. Barnes, R. Sellwood, 1987, British Journal of Cancer.

Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems

D. Barnes, B. Jasani, A. Rhodes, 2000, Journal of clinical pathology.

Response of metastatic breast cancer to trastuzumab?

D. Miles, D. Barnes, 2000, The Lancet.

IMMUNOHISTOCHEMICAL EVALUATION OF BIOLOGICAL MARKERS IN MAMMARY CARCINOMA IN SITU: CORRELATION WITH MORPHOLOGICAL FEATURES AND RECENTLY PROPOSED SCHEMES FOR HISTOLOGICAL CLASSIFICATION

L. Bobrow, D. Barnes, R. Millis, 1996 .

A mini-column method for routine measurement of human prostatic androgen receptors.

D. Barnes, N. Blacklock, S. Bowman, 1985, Journal of steroid biochemistry.

Breast cancer and a proto-oncogene.

D. Barnes, 1989, BMJ.

p53 immunoreactivity in breast cancer tissues does not deteriorate in stored paraffin sections

D. Barnes, C. Gillett, A. Hanby, 1998 .

p53 immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer

Philip Smith, D. Miles, D. Barnes, 1997, International journal of cancer.

p21(WAF1) expression and endocrine response in breast cancer.

I. Ellis, J. Robertson, R. Nicholson, 1999, The Journal of pathology.

Combined loss of BRCA1/BRCA2 in grade 3 breast carcinomas

B. Gusterson, D. Kelsell, D. Barnes, 1996, The Lancet.

Comparison of DNA interstrand cross-linking and strand breakage by 1,3-bis(2-chloroethyl)-1-nitrosourea in polyamine-depleted and control human adenocarcinoma cells.

D. Barnes, J. Seidenfeld, L. Erickson, 1987, Cancer research.

Molecular expression of epitopes recognized by monoclonal antibodies HMFG‐1 and HMFG‐2 in human breast cancers: Diversity, variability and relationship to prognostic factors

A. Howell, D. Barnes, J. Turnbull, 1986, International journal of cancer.

Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia

D. Barnes, C. Gillett, R. Millis, 1998, The Journal of pathology.

Flow cytometric characterisation of proliferating cell nuclear antigen using the monoclonal antibody PC10.

D. Lane, G. Wilson, R. Camplejohn, 1992, European journal of cancer.

l-/3-D-Arabinofuranosylcytosine and Hydroxyurea Production of Cytotoxic Synergy with cis-Diamminedichloroplatinum(II) and Modification of Platinum-induced DNA Interstrand Cross-Linking1

R. Fisher, K. Albain, D. Barnes, 2006 .

The value of rapid functional assays of germline p53 status in LFS and LFL families

R. Eeles, R. Camplejohn, D. Barnes, 2000, British Journal of Cancer.

Two methods for measurement of oestradiol-17 beta and progesterone receptors in human breast cancer and correlation with response treatment.

D. Barnes, G. Ribeiro, L. G. Skinner, 1977, European journal of cancer.

Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some, neoplasms

D. Lane, R. Camplejohn, P. Hall, 1990, The Journal of pathology.

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.

A. Harris, S. Love, D. Altman, 1991, British Journal of Cancer.

Serum glycoprotein hormone alpha subunit, hormone receptors and disease stage in patients with breast cancer.

D. Barnes, R. Swindell, J. Howat, 1980, British Journal of Cancer.

Absence of rearrangements in the tumour susceptibility gene TSG101 in human breast cancer

R. Weinberg, D. Barnes, P. Steiner, 1997, Nature Genetics.

Measurement of oestradiol receptors by five institutions on common tissue samples.

D. Barnes, R. King, R. Leake, 1978, British Journal of Cancer.

Leaders Determination of cell proliferation

D. Barnes, C. Gillett, 2003 .

Determination of cell proliferation

D. Barnes, C. Gillett, 1995, Clinical molecular pathology.

Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis?

D. Barnes, E. Dublin, D. Levison, 1993, Human pathology.

The expression of milk fat globule antigens within human mammary tumours: relationship to steroid hormone receptors and response to endocrine treatment.

A. Howell, D. Barnes, L. Turnbull, 1989, European journal of cancer & clinical oncology.

Expression of differentiation antigens within human mammary tumours is related to response to endocrine therapy and survival

A. Howell, D. Barnes, R. Swindell, 1988, International journal of cancer.

Studies of clonal cell lines developed from primary breast cancers indicate that the ability to undergo morphogenesis IN vitro is lost early in malignancy

J. Bartek, J. Bártková, J. Taylor‐Papadimitriou, 1992, International journal of cancer.

Triple hormone-receptor assay: a more accurate predictive tool for the treatment of advanced breast cancer?

D. Barnes, G. Ribeiro, L. G. Skinner, 1979, British Journal of Cancer.

Regional variation of cytosol androgen receptors throughout the diseased human prostate gland

D. Barnes, N. Blacklock, Susan P. Bowman, 1986, The Prostate.

KiSl—A novel monoclonal antibody which recognizes proliferating cells: Evaluation of its relationship to prognosis in mammary carcinoma

Philip Smith, R. Parwaresch, D. Barnes, 1992, The Journal of pathology.

The Cytotoxic and DNA Damaging Effects of Ethylcholine Mustard Aziridinium Ion (AF64A)

D. Barnes, 1989 .

Abnormal expression of wild type p53 protein in normal cells of a cancer family patient

D. Lane, L. Bobrow, B. Vojtesek, 1992, The Lancet.

Advances in Brief Epstein-Barr Virus in Epithelial Cell Tumors : A Breast Cancer Study 1

I. Fentiman, D. Barnes, B. Griffin, 2006 .

A microsatellite within the MUC1 locus at 1q21 is altered in the neoplastic cells of breast cancer patients.

D. Swallow, D. Barnes, S. Gendler, 1998, Cancer genetics and cytogenetics.

Cyclin D1 in mammary carcinoma

D. Barnes, 1997, The Journal of pathology.

Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer.

G. Peters, D. Barnes, V. Fantl, 1990, European journal of cancer.

Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer

Tatjana Crnogorac-Jurcevic, Corrado D'Arrigo, Louise Reynolds, 2003, Oncogene.

BAG‐1 expression in human breast cancer: interrelationship between BAG‐1 RNA, protein, HSC70 expression and clinico‐pathological data

R. Poulsom, A. Hanby, D. Barnes, 2002, The Journal of pathology.

STEROID-HORMONE RECEPTORS AND SURVIVAL AFTER FIRST RELAPSE IN BREAST CANCER

A. Howell, V. Bramwell, D. Barnes, 1984, The Lancet.

Cyclin‐dependent kinase inhibitor p27Kipl expression and interaction with other cell cycle‐associated proteins in mammary carcinoma

Philip Smith, Xin Lu, G. Peters, 1999, The Journal of pathology.

Tumour grade does not change between primary and recurrent mammary carcinoma.

D. Barnes, P. Smith, R. Millis, 1998, European journal of cancer.

p21WAF1 expression and endocrine response in breast cancer

I. Ellis, J. Robertson, R. Nicholson, 1999 .

Retinoblastoma and p16 proteins in mammary carcinoma: Their relationship to cyclin D1 and histopathological parameters

Philip Smith, G. Peters, D. Barnes, 1998, International journal of cancer.

Retention of the expression of E‐cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast

D. Miles, A. Hanby, D. Barnes, 2001, The Journal of pathology.

Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions.

C. Mathew, A. Cleton-Jansen, D. Callen, 2001, Cancer research.

of Candidate Regions 712 Breast Tumors Reveals Factors that Influence Delineation Loss of Heterozygosity Mapping at Chromosome Arm 16 q in Updated

C. Mathew, A. Cleton-Jansen, C. Cornelisse, 2001 .

Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers.

D. Barnes, W. Gullick, C. Gillett, 2000, Cancer research.

The locus of the polymorphic epithelial mucin (PEM) tumour antigen on chromosome 1q21 shows a high frequency of alteration in primary human breast tumours

D. Barnes, T. Duhig, E. Cohen, 1990, International journal of cancer.

The localization of the insulin‐like growth factor receptor 1 (IGFR‐1) in benign and malignant breast tissue

Philip Smith, L. Thomsen, L. Happerfield, 1997, The Journal of pathology.

The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease.

D. Barnes, R. Swindell, M. Harris, 1983, British Journal of Cancer.

Cyclin D1 and prognosis in human breast cancer

G. Peters, D. Barnes, C. Gillett, 1996, International journal of cancer.

Family history and survival in premenopausal breast cancer.

D. Miles, D. Barnes, S. Hodgson, 1998, British Journal of Cancer.

Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer.

N K Spurr, C. Wolf, D. Barnes, 1993, Carcinogenesis.

MSI‐low, a real phenomenon which varies in frequency among cancer types

W. Foulkes, W. Bodmer, S. Halford, 2003, The Journal of pathology.

M. Dowsett, J. Salter, S. Johnston, 1999, International journal of cancer.

DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast.

A. Howell, D. Barnes, L. Turnbull, 1987, British Journal of Cancer.

Oestrogen and progesterone receptors in breast cancer: past, present and future

D. Barnes, A. Hanby, 2001, Histopathology.

The interaction of oestrogen receptor status and pathological features with adjuvant treatment in relation to survival in patients with operable breast cancer: a retrospective study of 2660 patients.

I. Fentiman, D. Barnes, C. Gillett, 2004, Endocrine-related cancer.

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.

I. Ellis, R. Blamey, R. Nicholson, 1995, British Journal of Cancer.

Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation.

B. Vojtesek, D. Barnes, C. Gillett, 1994, British Journal of Cancer.

Expression of the ERBB3 gene product in breast cancer.

D. Barnes, N. Lemoine, E. Dublin, 1992, British Journal of Cancer.

Immunohistochemical detection of steroid receptors in breast cancer: a working protocol

D Barnes, T Anderson, S. Pinder, 2000, Journal of clinical pathology.

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

D. Miles, D. Barnes, R. Rubens, 1999, British Journal of Cancer.

Mitotic counts provide additional prognostic information in grade II mammary carcinoma

A. Hanby, D. Barnes, C. Gillett, 2002, The Journal of pathology.

The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast.

D. Barnes, R. Swindell, M. Harris, 1985, British Journal of Cancer.

Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment.

A. Howell, D. Barnes, R. Swindell, 1987, Cancer research.

An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.

D. Altman, D. Barnes, G. Lammie, 1988, British Journal of Cancer.

Association between loss of heterozygosity of BRCA1 and BRCA2 and morphological attributes of sporadic breast cancer

D. Bishop, D. Kelsell, D. Barnes, 2000, International journal of cancer.

Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?

D M Barnes, Philip Smith, J. Bártková, 1992, European journal of cancer.

Loss of heterozygosity of the oestrogen receptor gene in breast cancer.

C. Mathew, L. Bobrow, D. Barnes, 1995, British Journal of Cancer.

Investigations on a clinically and functionally unusual and novel germline p53 mutation

G R Taylor, D M Barnes, G. Taylor, 2002, British Journal of Cancer.

Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry.

R. Camplejohn, D. Barnes, R. Rubens, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OESTROGEN RECEPTOR STATUS AND MANAGEMENT OF BREAST CANCER

D. Barnes, J. Howat, 1981, The Lancet.

The clinical value of multiple steroid receptor assays in breast cancer management

D. Barnes, G. Ribeiro, L. G. Skinner, 1980, Cancer.

Demystified ... cell cycle.

D M Barnes, D. Barnes, C. Gillett, 1998, Molecular pathology : MP.

High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers.

S. Shousha, P. Hall, D. Barnes, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Effect of c‐erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil

Philip Smith, D. Miles, D. Barnes, 1999, International journal of cancer.

DNA index, S-phase fraction, histological grade and prognosis in breast cancer.

R. Camplejohn, D. Barnes, R. Rubens, 1990, British Journal of Cancer.

p53 protein detected by immunohistochemical staining is not always mutant.

D. Bishop, D. Barnes, S. Hodgson, 1993, Disease markers.

Heterogeneity in Li-Fraumeni families: p53 mutation analysis and immunohistochemical staining.

L. Bobrow, D. Barnes, C. MacGeoch, 1995, Journal of medical genetics.

Cell proliferation measured by MIB1 and timing of surgery for breast cancer.

D. Barnes, C. Gillett, P. Smith, 1998, British Journal of Cancer.

Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.

J. Bártková, D. Barnes, W. Gullick, 1990, Human pathology.

Evaluation of infiltrating ductal carcinomas with a DCIS component: correlation of the histologic type of the in situ component with grade of the infiltrating component.

Philip Smith, D. Barnes, P. Smith, 1994, Seminars in diagnostic pathology.

Oestrogen receptors and survival in early breast cancer

D. Barnes, J. Howat, T. Howell, 1982 .

Comparison of three cell cycle associated antigens as markers of proliferative activity and prognosis in breast carcinoma.

R. Camplejohn, D. Barnes, C. Gillett, 1993, Journal of clinical pathology.

Introduction to Oncogenes and Molecular Cancer Medicine.

D. Barnes, 1999 .

Endocrine therapy for advanced carcinoma of the breast: effect of tumor heterogeneity and site of biopsy on the predictive value of progesterone receptor estimations.

A. Howell, D. Barnes, R. Swindell, 1987, Cancer research.

Expression ofepidermal growth factor receptor (EGF-R)innon-small cell lung cancer.Useofarchival tissue andcorrelation ofEGF-Rwith histology, tumoursize, nodestatus andsurvival

P. Hasleton, D. Barnes, N. Thatcher, 1989 .

An immunohistochemical study of the presence of c‐erbB‐2 protein in Paget's disease of the nipple

D. Barnes, W. Gullick, R. Millis, 1989, Histopathology.

Systemic Treatment and Survival in Carcinoma of the Breast

A. Howell, D. Barnes, M. Jones, 1986 .

Survival of premenopausal breast carcinoma patients in relation to menstrual cycle timing of surgery and estrogen receptor/progesterone receptor status of the primary tumor

I. Fentiman, D. Barnes, C. Gillett, 1999, Cancer.

TUMOUR INFORMATION FROM NEEDLE BIOPSY

A. Howell, D. Barnes, L. Turnbull, 1986, The Lancet.

BAG-1 immunostaining and survival in early breast cancer.

P. Townsend, D. Barnes, A. Bateman, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breast

D. Barnes, C. Gillett, H. Potts, 2000, International Journal of Cancer.

Ampli ® cation and over-expression of the MDM 2 gene in human soft tissue tumours

C. Cooper, B. Gusterson, C. Fisher, 2014 .

Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay.

D M Barnes, R. Camplejohn, D. Barnes, 2000, The Journal of molecular diagnostics : JMD.

Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.

J. Bartek, G. Peters, D. Barnes, 1994, Cancer research.

Amphiregulin and cripto overexpression in breast-cancer - relationship with prognosis and clinical and molecular-variables.

L. Bobrow, D. Barnes, W. Gullick, 1995, International journal of oncology.

Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression.

R. Poulsom, D. Barnes, E. Dublin, 1998, The American journal of pathology.

Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems

D. Barnes, B. Jasani, A. Rhodes, 2000, Journal of clinical pathology.

The Molecular Basis of Cell Cycle and Growth Control.

D. Barnes, C. Gillet, 2000 .

477 Steroid receptors in human meningioma

H. Whitwell, D. Barnes, K. S. Paul, 1983 .

Oestrogen receptors and survival in early breast cancer.

D. Barnes, J. Howat, T. Howell, 1982, British medical journal.

Endocrine Relationships in Breast Cancer

D. Barnes, 1982, British Journal of Cancer.